NCT07185997 2026-04-16Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon MutationsArriVent BioPharma, Inc.Phase 3 Recruiting480 enrolled
NCT04614103 2026-04-15Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung CancerIovance Biotherapeutics, Inc.Phase 2 Recruiting170 enrolled
NCT03093116 2026-04-03TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 4 FDA
NCT06128551 2026-02-10Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid TumorsRevolution Medicines, Inc.Phase 1/2 Recruiting534 enrolled
NCT05361174 2024-12-05A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung CancerIovance Biotherapeutics, Inc.Phase 1/2 Recruiting53 enrolled